Augmented expression of chromogranin A and serotonin in peri-malignant benign prostate epithelium as compared to adenocarcinoma

Pathology Research and Practice

Volumn 200, Issue 7-8, 2004, Pages 493-499

  Sion Vardy, Netta ^a,b   Tzikinovsky, Alina ^b   Bolotyn, Arkady ^b   Segal, Shraga ^b   Fishman, Daniel ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Adenocarcinoma; Neuroendocrine markers; Prostate

Indexed keywords

ADRENOMEDULLIN; BIOLOGICAL MARKER; CHROMOGRANIN A; FORMALDEHYDE; NEURON SPECIFIC ENOLASE; PARAFFIN; SEROTONIN;

ADENOCARCINOMA; ARTICLE; CANCER INVASION; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; NODULAR HYPERPLASIA; PROSTATE; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TUMOR GROWTH; WILCOXON SIGNED RANKS TEST;

EID: 10644297142     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prp.2004.06.002     Document Type: Article

References (30)

1. G. Aumuller, M. Leonhardt, M. Janssen, L. Konrad, A. Bjartell, P.A. Abrahamsson, Neurogenic origin of human prostate endocrine cells, Urology 53 (1999) 1041-1048.
2. H. Bonkhoff, Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer, Eur. Urol. 30 (1996) 201-205.
3. H. Bonkhoff, K. Remberger, Morphogenetic concepts of normal and abnormal growth in the human prostate, Virchows Arch. 433 (1998) 195-202.
4. H. Bonkhoff, U. Stein, K. Remberger, Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers, Human Pathol. 25 (1994) 42-46.
5. T. Burchardt, M. Burchardt, M.W. Chen, Y. Cao, A. de la Taille, A. Shabsigh, O. Hayek, T. Dorai, R. Buttyan, Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo, J. Urol. 162 (1999) 1800-1805.
6. J.W. Chiao, T.C. Hsieh, W. Xu, R.J. Sklarew, R. Kancherla, Development of human prostate cancer cells to neuroendocrine-like cells by interleukin-1, Int. J. Oncol. 15 (1999) 1033-1037.
7. R.J. Cohen, G. Glezerson, Z. Haffejee, Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer, Arch. Pathol. Lab. Med. 116 (1992) 65-66.
8. P.D. Deeble, D.J. Murphy, S.J. Parsons, M.E. Cox, Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells, Mol. Cell Biol. 21 (2001) 8471-8482.
9. L.J. Deftos, Prostate carcinoma: production of bioactive factors, Cancer 88 (2000) 3002-3008.
10. J. Hansson, P.A. Abrahamsson, Neuroendocrine differentiation in prostatic carcinoma, Scand. J. Urol. Nephrol. Suppl. 212 (2003) 28-36.
11. N.M. Hoosein, C.J. Logothetis, L.W. Chung, Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells, J. Urol. 149 (1993) 1209-1213.
12. D.J. Hryb, A.M. Nakhla, S.M. Kahn, J. St George, N.C. Levy, N.A. Romas, W. Rosner, Sex hormone-binding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector, J. Biol. Chem. 277 (2002) 266-2622.
13. T. Hvamstad, A. Jordal, N. Hekmat, E. Paus, S.D. Fossa, Neuroendocrine serum tumour markers in hormone-resistant prostate cancer, Eur. Urol. 44 (2003) 215-221.
14. T. Ito, S. Yamamoto, Y. Ohno, K. Namiki, T. Aizawa, A. Akiyama, M. Tachibana, Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence, Oncol. Rep. 8 (2001) 1221.
15. M.E. Jelbart, P.J. Russell, P. Russell, J. Wass, M. Fullerton, E.J. Wills, D. Raghavan, Site-specific growth of the prostate xenograft line UCRU-PR-2, Prostate 14 (1989) 163-175.
16. T. Jiborn, A. Bjartell, P.A. Abrahamsson, Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment, Urology 51 (1998) 585-589.
17. J. Jongsma, M.H. Oomen, M.A. Noordzij, J.C. Romijn, T.H. van Der Kwast, F.H. Schroder, G.J. van Steenbrugge, Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines, Prostate 42 (2000) 34-44.
18. J. Jongsma, M.H. Oomen, M.A. Noordzij, W.M. Van Weerden, G.J. Martens, T.H. van der Kwast, F.H. Schroder, G.J. van Steenbrugge, Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation, Prostate 50 (2002) 203-215.
19. L.I. Larsson, L. Morch-Jorgensen, D.M. Hougaard, Cellular and subcellular localization of polyamines cytochemical methods providing new clues to polyamine function in normal and neoplastic cells, Histochemistry 76 (1982) 159-174.
20. K. Minamiguchi, M. Kawada, T. Someno, M. Ishizuka, Androgen-independent prostate cancer DU145 cells suppress androgen-dependent growth of prostate stromal cells through production of inhibitory factors for androgen responsiveness, Biochem. Biophys. Res. Commun. 306 (2003) 629-636.
21. J. Pinski, A.V. Schally, G. Halmos, K. Szepeshazi, Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice, Int. J. Cancer 55 (1993) 963-967.
22. A. Plonowski, J.L. Varga, A.V. Schally, M. Krupa, K. Groot, G. Halmos, Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity, Int. J. Cancer 98 (2002) 624-629.
23. P. Rocchi, F. Boudouresque, A.J. Zamora, X. Muracciole, E. Lechevallier, P.M. Martin, L. Ouafik, Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines, Cancer Res. 61 (2001) 1196-1206.
24. H. Rumpold, E. Heinrich, G. Untergasser, M. Hermann, G. Pfister, E. Plas, P. Berger, Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro, Prostate 53 (2002) 101-108.
25. A. Tsukise, K. Yamada, Secretory glycoconjugates in the epithelium of the goat prostate, Histochem. J. 19 (1987) 345-350.
26. J.A. Tuxhorn, G.E. Ayala, D.R. Rowley, Reactive stroma in prostate cancer progression, J. Urol. 166 (2001) 2472-2483.
27. J.A. Tuxhorn, G.E. Ayala, M.J. Smith, V.C. Smith, T.D. Dang, D.R. Rowley, Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling, Clin. Cancer Res. 8 (2002) 2912-2923.
28. J.A. Tuxhorn, S.J. McAlhany, T.D. Dang, G.E. Ayala, D.R. Rowley, Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model, Cancer Res. 62 (2002) 3298-3307.
29. J.T. Wu, M.E. Astill, G.H. Liu, R.A. Stephenson, Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients, J. Clin. Lab. Anal. 12 (1998) 20-25.
30. S. Zelivianski, M. Verni, C. Moore, D. Kondrikov, R. Taylor, M.F. Lin, Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype, Biochim. Biophys. Acta 1539 (2001) 28-43.